Deep-tech firm ImVitro has introduced a $2.5M seed spherical led by LDV Capital, with co-investors together with MMC Ventures, Tiny VC, Fly Ventures, and Compound VC. The corporate consists of a dozen specialists concerned with AI, medtech, and regulatory affairs. The workforce is led by Dr. Alexandra Boussommier, a biomedical engineer educated in Switzerland, the UK and the US.
EMBRYOLY Platform for IVF Course of
ImVitro developed the B2B SaaS platform EMBRYOLY, which applies laptop imaginative and prescient and synthetic intelligence (AI) to the IVF fertility imaging course of. The corporate works to reduce failed transfers within the IVF course of, in addition to enhance high quality management and transparency for sufferers.
Over a dozen clinics in Europe depend on EMBRYOLY, with greater than 1,500 IVF cycles being processed by the platform.
ImVitro developed an working system that mixes cell tradition and AI to deal with infertility. The method entails AI-powered automation within the embryo analysis course of with EMBRYOLY analyzing movies from microscopes to avoid wasting time for clinicians whereas growing transparency. This course of additionally eliminates human errors and delivers dependable predictions. Clinics can even use the platform to offer entry to a affected person portal that delivers simplified lab outcomes.
The platform is CE marked and has benchmarked its efficiency in opposition to 13 embryologists in a retrospective medical trial.
Whereas different options are restricted to visible info or the affected person’s age, ImVitro can analyze greater than 30 medical knowledge factors to create a hybrid rating. These knowledge factors embody the affected person’s BMI, uterus receptivity, spermatozoa mobility, and extra. All of this results in improved accuracy and customized and standardized outcomes.
Dr. Alexandra Boussommier can also be Founder and CEO of ImVitro.
“By taking into consideration knowledge in regards to the sufferers and their remedy, EMBRYOLY predicts extra precisely the possibilities an embryo has to result in a being pregnant and offers extra clear and customized suggestions,” Dr. Boussommier stated.
The brand new funding will go in direction of including new hires within the technical and gross sales workforce. It can additionally assist the corporate increase to the U.S. market and develop new options for the software program.
“We’re very excited to be coming into this new chapter that may consolidate our AI-driven software program not solely as a instrument that minimizes failed IVF remedies, but in addition one which will increase workflow effectivity within the IVF lab and offers a bridge between docs and sufferers so as to add transparency to the advanced multi-step course of that’s IVF,” Dr. Boussommier continued.
Dr. Xavier Pollet-Villard is Director of the Nataliance IVF and Andrology laboratory.
“ImVitro helps embryologists and sufferers at our clinic to navigate the advanced means of IVF,” he says. “It not solely will increase the effectivity of the work that we do but in addition offers much-needed transparency. Their AI-powered platform EMBRYOLY seamlessly connects to our know-how stack and helps us make data-driven choices about embryos that we observe in our lab which then result in profitable pregnancies.”
Phrases From Traders
Evan Nisselson is Founder and Common Associate at LDV Capital.
“We at LDV Capital are thrilled to accomplice with Dr. Alexandra Boussommier and the good workforce at ImVitro to deliver EMBRYOLY to market throughout the globe so thousands and thousands of individuals can enhance their probability of getting a profitable being pregnant by way of the IVF Fertility course of,” stated Nisselson. “ImVitro will ship a leapfrog technical resolution to the IVF fertility imaging course of by leveraging laptop imaginative and prescient and synthetic intelligence which has been a core experience of our LDV Capital agency since being based in 2012.”
Charlotte Barttelot is Principal at MMC Ventures.
“We’ve been researching the fertility panorama, and the IVF course of has not improved because the first IVF child over 40 years in the past,” Barttelot stated. “ImVitro’s workforce combines deep-tech experience and entrepreneurship, leveraging laptop imaginative and prescient and AI to extend the share of profitable pregnancies. We’re proud to be a part of their journey.”
